Prescient Therapeutics Investor Replay – 10 June
Prescient Therapeutics Investor Briefing Prescient Therapeutics CEO and MD Steven Yatomi-Clarke and Senior VP of...
Prescient Therapeutics Investor Briefing Prescient Therapeutics CEO and MD Steven Yatomi-Clarke and Senior VP of...
Melbourne-based Prescient will focus development of its OmniCAR platform into three programs: the blood cancer...
Prescient Therapeutics (PTX) has announced three internal development programs for its immune receptor technology platform,...
Following more than a decade of treatments, cancer survivor Laurie Adami now plans to tackle...
An American woman who owes her life to a bespoke cancer treatment is speaking out...
Laurie Adami has had a long and intricate journey with blood cancer, after being diagnosed...
When local synthetic antibiotics developer Recce Pharmaceuticals announced they had entered into an antiviral Sars-CoV-2...
Prescient Therapeutics (ASX: PTX) Chief Executive Officer Steven Yatomi-Clarke joins Small Caps to discuss the...
PTX has acquired the exclusive global licence to a universal immune receptor (UIR) platform from...

This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.